On 17 September 2024, GlaxoSmithKline (GSK) announced that Japan’s Ministry of Health has accepted for review a new drug application for Blenrep® (belantamab mafodotin) in combination with BorDex (bortezomib plus dexamethasone) or PomDex (pomalidomide plus dexamethasone) as a treatment for relapsed or refractory multiple myeloma.
This follows last week’s announcement by GSK that China’s National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation (BTD) for Blenrep® in combination with BorDex for the same indication.